Ivan Zelepukin
Post doc. vid Institutionen för läkemedelskemi; Theranostics
- E-post:
- ivan.zelepukin@ilk.uu.se
- Besöksadress:
- Dag Hammarskjöldsv 14C, 3tr
- Postadress:
- Dag Hammarskjöldsv 14C, 3tr
751 83 Uppsala
Ladda ned kontaktuppgifter för Ivan Zelepukin vid Institutionen för läkemedelskemi; Theranostics
Stipendiat vid Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerprecisionsmedicin; Forskargrupp Vladimir Tolmachev
- E-post:
- ivan.zelepukin@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postadress:
- Rudbecklaboratoriet
751 85 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Urval av publikationer
- MPS blockade with liposomes controls pharmacokinetics of nanoparticles in a size-dependent manner (2024)
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery (2024)
Senaste publikationer
- MPS blockade with liposomes controls pharmacokinetics of nanoparticles in a size-dependent manner (2024)
- Laser-Synthesized Germanium Nanoparticles as Biodegradable Material for Near-Infrared Photoacoustic Imaging and Cancer Phototherapy (2024)
- Laser-synthesized plasmonic HfN-based nanoparticles as a novel multifunctional agent for photothermal therapy (2024)
- Boron Nanoparticle-Enhanced Proton Therapy (2024)
- Modification of contact lenses via metal-organic frameworks for glaucoma treatment (2024)
Alla publikationer
Artiklar
- MPS blockade with liposomes controls pharmacokinetics of nanoparticles in a size-dependent manner (2024)
- Laser-Synthesized Germanium Nanoparticles as Biodegradable Material for Near-Infrared Photoacoustic Imaging and Cancer Phototherapy (2024)
- Laser-synthesized plasmonic HfN-based nanoparticles as a novel multifunctional agent for photothermal therapy (2024)
- Boron Nanoparticle-Enhanced Proton Therapy (2024)
- Modification of contact lenses via metal-organic frameworks for glaucoma treatment (2024)
- Bismuth nanoparticles-enhanced proton therapy (2024)
- Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery (2024)